Type 2 Diabetes · Currently recruiting
Zenagamtide vs. Semaglutide (AMBITION 3)
Study of once-weekly zenagamtide injection compared with higher-dose once-weekly semaglutide in adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both.
Study details
Condition: Type 2 Diabetes
Status: Recruiting
Protocol: NN9489-8035
Site: EndoTrials Clinical Research Center, La Mesa, California
Full eligibility criteria are set by the study protocol. Our research team will review them with you, explain what participation involves, including visits, procedures and compensation where applicable, and answer your questions before you decide. Participation is voluntary, and you can withdraw at any time.
EndoTrials is the clinical research center of Diabetes & Endocrine Specialists, led by Darius A. Schneider, MD, PhD.